Trial Profile
Observational study of Sativex in patients with multiple sclerosis-related spasticity.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2015
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Multiple sclerosis; Muscle spasticity
- Focus Therapeutic Use
- Acronyms MOVE-2
- 24 Oct 2012 New trial record
- 12 Oct 2012 Results were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in October 2012.
- 12 Oct 2012 A cost-effectiveness analysis has been conducted using data from this trial.